Supplementary




Figure S1 AFP levels throughout the disease course. Green diamond, indicates the points in the timeline in which AFP was measured. Length of one cycle is 21 days. AFP, alpha-fetoprotein.

Table S1 HFA-ICOS cardio-oncology baseline risk stratification for VEGFi cardiotoxicity (13)

VEGFi cardiotoxicity	Risk factors	Risk score	ESC guidelines
Very high-risk factors	Heart failure* or cardiomyopathy	Presence of one or both puts the patient at very high risk (≥20%)	Refer to cardio-oncology or cardiology assessment, to optimize risk factors and provide a personalized management plan
	Arterial vascular disease*		
High-risk factors	 Venous thrombosis* 	Presence of one or more puts the patient at high risk (10–19%)	Refer to cardio-oncology or cardiology assessment, to optimize risk factors and provide a personalized management plan
	• Baseline LVEF <50%*		
	• QTc ≥480 ms		
	 Age ≥75 years, hypertension* 		
	Prior anthracycline exposure		
Medium risk factors	Two points each: • Borderline LVEF of 50–54%	If ≥5 points, the patient is at high risk (10–19%)	Refer to cardio-oncology or cardiology assessment, to optimize risk factors and provide a personalized management plan
	• 450 ms ≤QTc <480 ms (men) or 460 ms ≤QTc <480 ms (women)		
	Arrythmia	If 2–4 points, the patient is at medium risk (2–9%)	Closely monitor for cardiovascular health. Consider cardio-oncology or cardiology referral
	One points each: • Elevated baseline troponin		
	 Elevated baseline BNP or NT-proBNP* 		
	• Age 65–74 years*	If <2 points, the patient is at low risk (<2%)	Continue treatment with appropriate cardiovascular surveillance
	• Diabetes mellitus*		
	Chronic kidney disease		
	Proteinuria		
	Hyperlipidemia*		
	 Prior radiotherapy to the left chest or mediastinum 		
	Current smoker		
	 Obesity* 		

^{*,} indicates the risk factors that were present in the patient discussed. HFA, Heart Failure Association of the ESC; ESC, European Society of Cardiology; ICOS, International Cardio-oncology Society; VEGFi, vascular endothelial growth factor inhibitor; LVEF, left ventricle ejection fraction; QTc, corrected QT interval; BNP, brain natriuretic peptide; NT-proBNP, N-terminal pro B-type natriuretic peptide.